Kyolic Presenting at Joint Vascular Conference

MISS IONVIEJO,Calif.—Wakunaga of America Co. announced researchers from the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and from Munich University Medical Center are scheduled to present new research about Kyolic Aged Garlic Extract™ (AGE) at a joint-vascular conference to take place in September at the University of Munich, Germany. The new studies address AGE’s ability to slow the progression of plaque in coronary arteries, and how it benefits endothelial and platelet function. “This symposium will present new and powerful research on AGE,” said Toshi Ide, research and development director, Wakunaga of America (www.Wakunaga.com). “These studies will demonstrate that AGE not only addresses risk factors of heart disease, but also go beyond the risk factor stage, which is a very important point.” Previous studies have examined AGE’s ability to lower cholesterol and homocysteine levels, inhibit cholesterol oxidation, thin the blood, stimulate circulation and more.